9209 Safety of romiplostim for treatment of severe chemotherapy induced thrombocytopenia (CIT) in patients with lymphoma receiving multi-cycle chemotherapy: results from an open-label dose- and schedule-finding study

M.Fanale; P.Stiff; K.Noonan; J.McCoy; M.Rutstein; C.Moskowitz

首页> 外文期刊>European Journal of Cancer Supplements >9209 Safety of romiplostim for treatment of severe chemotherapy induced thrombocytopenia (CIT) in patients with lymphoma receiving multi-cycle chemotherapy: results from an open-label dose- and schedule-finding study

【24h】

9209 Safety of romiplostim for treatment of severe chemotherapy induced thrombocytopenia (CIT) in patients with lymphoma receiving multi-cycle chemotherapy: results from an open-label dose- and schedule-finding study

机译：9209 romiplostim在接受多周期化疗的淋巴瘤患者中治疗严重化疗诱导的血小板减少症（CIT）的安全性：一项开放性剂量和时间表研究的结果

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共1页
作者
M.Fanale; P.Stiff; K.Noonan; J.McCoy; M.Rutstein; C.Moskowitz;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. [J] . Demeter J, Istenes I, Fodor A, Pathology oncology research: POR . 2011,第1期

机译：罗米洛司汀治疗套细胞淋巴瘤患者化疗诱导的血小板减少症（CIT）的疗效。
2. Efficacy of Romiplostim in the Treatment of Chemotherapy Induced Thrombocytopenia (CIT) in a Patient with Mantle Cell Lymphoma [J] . András Matolcsy, Anikó Fodor, Erika Valasinyószki, Pathology oncology research: POR . 2010,第1期

机译：罗米普司汀对套细胞淋巴瘤患者化疗诱导的血小板减少症（CIT）的治疗效果
3. 9248 Safety of romiplostim for treatment of chemotherapy-induced thrombocytopenia (CIT) in patients with advanced non-small cell lung cancer (NSCLC) [J] . R.Natale, V.Charu, W.Schütte, European Journal of Cancer Supplements . 2009,第2期

机译：9248 romiplostim治疗晚期非小细胞肺癌（NSCLC）化疗引起的血小板减少症（CIT）的安全性
4. Cancer support advice (CANadvice) m-health system for home monitoring and symptom management of patients receiving oral chemotherapy treatment [C] . Sobnath D., Philip N., Kayyali R., 2014 4th International Conference on Wireless Mobile Communication and Healthcare - "Transforming healthcare through innovations in mobile and wireless technologies" . 2014

机译：癌症支持与建议（CANadvice）移动医疗系统，用于接受口服化疗的患者的家庭监测和症状管理
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. A Randomized Double-Blind Placebo-Controlled Study of the Safety and Efficacy of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy: Results of the Korean South West Oncology Group (KSWOG) Study [O] . So-Yeon Jeon, Hye Sook Han, Woo Kyun Bae, 2019

机译：奥氮平预防中度致呕性化学疗法患者中化学疗法诱发的恶心和呕吐的安全性和有效性的随机双盲安慰剂对照研究：韩国西南肿瘤组（KSWOG）的研究结果
7. Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens [O] . Hingmire Sachin, Raut Nirmal 2015

机译：开放标签观察性研究，评估阿瑞吡坦对接受高致吐性化疗/中度致吐化疗方案化疗的印度患者化疗引起的恶心和呕吐预防的疗效和安全性

9209 Safety of romiplostim for treatment of severe chemotherapy induced thrombocytopenia (CIT) in patients with lymphoma receiving multi-cycle chemotherapy: results from an open-label dose- and schedule-finding study

著录项

相似文献

相关主题

期刊订阅